Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

CapitalMonk May. 12 at 9:39 PM

$PRAX Price: $343.20 (+3.43%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.46% RSI: 52.9 | Momentum: Moderate Volume: -12.0% vs avg Volatility: 3.03% Support: $310.01 | Resistance: $353.00 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

R84877P May. 12 at 7:50 PM

$PRAX Yes

0 · Reply

Quantumup May. 12 at 5:14 PM

Stifel reiterated $RAPP Buy; $56, and said: We remain Buy rated on RAPP following their 1Q26 report, where notably, the RAP-219 ph2 results in bipolar mania are now expected in 4Q26 (1H27 previously). $PRAX BHVN MPLT VNDA ALKS JAZZ UCBJY $XENE Here's what else Stifel said in its note to investors: https://x.com/Quantumup1/status/2054248241332412799?s=20

0 · Reply

Brianum2011 May. 11 at 12:37 PM

$INBX Holding this and $PRAX Great great future for both imo

0 · Reply

DonCorleone77 May. 10 at 3:33 PM

$XENE $PRAX Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo Wells Fargo analyst Benjamin Burnett raised the firm's price target on Xenon Pharmaceuticals (XENE) to $69 from $68 and keeps an Overweight rating on the shares. The firm sees a high probability of approval of azetukalner in focal onset seizures. However, Praxis Precision's Phase 3 vormatrigine POWER1 data creates some near term risk for Xenon, the analyst tells investors in a research note.

1 · Reply

MarketBeat May. 8 at 8:07 PM

Praxis Precision Medicines Q1 Earnings Call Highlights $PRAX #PraxisPrecisionMedicines #instantalerts #NASDAQ:PRAX https://www.marketbeat.c

0 · Reply

Quantumup May. 7 at 6:33 PM

Jefferies⬆️the PT on $PRAX to $550 (was $525) and reiterated at Buy while noting a Catalysts Rich 2026-2027 for Praxis' Neurology Pipeline. Here's what Jefferies had to say in its note to investors: In 2026-27, we see a rich set of catalysts across PRAX's neuro pipeline, including: (1) Vormatrigine (oral NaV), which has Phase II/III focal epilepsy data in Q2:26 ($750M+ oppty). (2) Relutrigine (oral NaV), which has a Sep 27, 2026 PDUFA in SCN2A/8A-DEE rare epilepsy ($600M+ oppty) as well as Phase III data in Q4:26 in all DEEs ($2B+ oppty), (3) Ulixacaltamide (oral calcium channel), which has a Jan 29, 2027 PDUFA in ET tremor ($3B+ oppty).

0 · Reply

R84877P May. 7 at 5:30 PM

$PRAX A lot of positive news about earnings and the future.

0 · Reply

AngusMacbeth May. 7 at 4:10 PM

$PRAX Added a few at $324. will add more if it drops a bit further.

0 · Reply

3_19 May. 7 at 2:06 PM

$PRAX Was anyone expecting profitable quarter ? I see how this market reacts.

2 · Reply

Praxis Precision assumed with a Buy at Truist

May 12, 2026, 7:20 PM EDT - 14 hours ago

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T16:03:31.000Z - 4 days ago

Praxis Precision price target lowered to $420 from $444 at Deutsche Bank

2026-05-08T13:50:27.000Z - 5 days ago

Praxis Precision price target raised to $166 from $130 at Wedbush

May 7, 2026, 8:30 AM EDT - 6 days ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 days ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 5, 2026, 4:01 PM EDT - 7 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 4:01 PM EDT - 8 days ago

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

2026-04-15T12:48:12.000Z - 4 weeks ago

Praxis Precision price target raised to $437 from $412 at Deutsche Bank

2026-04-14T11:42:59.000Z - 4 weeks ago

Praxis Precision announces FDA acceptance of ulixacaltamide NDA

Apr 14, 2026, 7:30 AM EDT - 4 weeks ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

2026-04-10T09:40:21.000Z - 4 weeks ago

Praxis Precision initiated with a Strong Buy at Raymond James

2026-04-09T20:30:17.000Z - 4 weeks ago

Praxis Precision initiated with a Strong Buy at Raymond James

2026-04-06T12:05:07.000Z - 5 weeks ago

Praxis Precision announces topline results from EMBRAVE Part A trial

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

2026-03-30T20:24:25.000Z - 6 weeks ago

Praxis Precision announces FDA acceptance for priority review of relutrigine NDA

Mar 30, 2026, 4:01 PM EDT - 6 weeks ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 2, 2026, 11:50 AM EST - 2 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-23T21:16:33.000Z - 2 months ago

Praxis Precision initiated with an Outperform at Wolfe Research

2026-02-20T14:51:00.000Z - 2 months ago

Praxis Precision price target raised to $700 from $500 at Truist

2026-02-20T13:21:10.000Z - 2 months ago

Praxis Precision price target raised to $130 from $95 at Wedbush

2026-02-20T12:41:32.000Z - 2 months ago

Praxis Precision price target raised to $412 from $357 at Deutsche Bank

2026-02-20T12:07:25.000Z - 2 months ago

Praxis Precision price target raised to $433 from $275 at Baird

2026-02-20T11:32:20.000Z - 2 months ago

Praxis Precision price target raised to $305 from $282 at Wells Fargo

Feb 19, 2026, 8:00 AM EST - 2 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 7:30 AM EST - 2 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 1:00 PM EST - 3 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 4:01 PM EST - 3 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 2, 2026, 9:57 AM EST - 3 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 8, 2026, 4:45 PM EST - 4 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 6, 2026, 11:15 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 4:03 PM EST - 4 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 11, 2025, 8:00 AM EST - 5 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 9, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 4, 2025, 4:10 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:01 PM EST - 5 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Nov 24, 2025, 1:00 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 20, 2025, 4:01 PM EST - 6 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 18, 2025, 8:30 AM EST - 6 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 6 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 7, 2025, 12:30 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 16, 2025, 11:45 PM EDT - 7 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 2:14 PM EDT - 7 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 7 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 8:00 AM EDT - 7 months ago

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 7:09 AM EDT - 7 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Sep 29, 2025, 7:00 AM EDT - 8 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 10, 2025, 8:30 AM EDT - 8 months ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:01 PM EDT - 8 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 2, 2025, 10:00 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Aug 25, 2025, 4:01 PM EDT - 9 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 7, 2025, 11:00 AM EDT - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 5:50 PM EDT - 10 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 10:00 AM EDT - 10 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 8:30 AM EDT - 10 months ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2025

Jul 17, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Jefferies Global Healthcare Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Status Update

May 2, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 7, 2025, 11:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Mar 17, 2025, 9:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: UBS Virtual CNS Day 2025

Mar 12, 2025, 2:30 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 9:10 AM EST - 1 year ago

Praxis Precision Medicines Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 11, 2025, 11:20 AM EST - 1 year ago

Praxis Precision Medicines Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:30 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Jan 15, 2025, 5:15 PM EST - 1 year ago

Praxis Precision Medicines Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 12, 2025, 9:00 PM EST - 1 year ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dec 18, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 1 year ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Dec 4, 2024, 2:00 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Nov 20, 2024, 5:00 AM EST - 1 year ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2024

Nov 11, 2024, 1:00 PM EST - 1 year ago

Praxis Precision Medicines Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Nov 6, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Earnings Call Transcript: Q3 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Sep 9, 2024, 12:00 PM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Study Result

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Sep 2, 2024, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

CapitalMonk May. 12 at 9:39 PM

0 · Reply

R84877P May. 12 at 7:50 PM

$PRAX Yes

0 · Reply

Quantumup May. 12 at 5:14 PM

0 · Reply

Brianum2011 May. 11 at 12:37 PM

$INBX Holding this and $PRAX Great great future for both imo

0 · Reply

DonCorleone77 May. 10 at 3:33 PM

1 · Reply

MarketBeat May. 8 at 8:07 PM

Praxis Precision Medicines Q1 Earnings Call Highlights $PRAX #PraxisPrecisionMedicines #instantalerts #NASDAQ:PRAX https://www.marketbeat.c

0 · Reply

Quantumup May. 7 at 6:33 PM

0 · Reply

R84877P May. 7 at 5:30 PM

$PRAX A lot of positive news about earnings and the future.

0 · Reply

AngusMacbeth May. 7 at 4:10 PM

$PRAX Added a few at $324. will add more if it drops a bit further.

0 · Reply

3_19 May. 7 at 2:06 PM

$PRAX Was anyone expecting profitable quarter ? I see how this market reacts.

2 · Reply

R84877P May. 7 at 2:00 PM

$PRAX Me, excited for the dip and buying!! 🙈

0 · Reply

Quantumup May. 7 at 1:19 PM

Raymond reiterated $RAPP Strong Buy; $66, and provided its thoughts on the stock. $XENE $PRAX BHVN MPLT VNDA JAZZ ALKS UCBJY Here's what Raymond James said in its note: https://x.com/Quantumup1/status/2052377029060726819?s=20

0 · Reply

StocktwitsEarnings May. 7 at 1:08 PM

$PRAX Q1 '26 Earnings Results & Recap Praxis Precision Medicines Inc. expects its $1.4B in cash, cash equivalents, and marketable securities as of March 31, 2026, to fund operating and capital expenditures into 2028, supporting research and clinical trials.

0 · Reply

Biotechster May. 6 at 9:46 PM

$PRAX FMR LLC (Fidelity) just disclosed a 7.7% stake via a 13G/A filing, increasing their position by nearly 800,000 shares to a total of 2.15M. This level of institutional accumulation is a highly notable footprint, particularly as we look ahead toward the ongoing NDA regulatory timelines and subsequent PDUFA dates. Coupled with the potential for upcoming mid-cap index inclusion and the resulting rebalancing volume, seeing smart money aggressively expand their position adds strong fundamental conviction to the current setup.

0 · Reply

3_19 May. 5 at 4:53 PM

$PRAX picked up a few @ 330 ugh

0 · Reply

Trainguy1 May. 4 at 8:37 PM

$PRAX The earnings call is on Thursday. https://investors.praxismedicines.com/node/11356/pdf

1 · Reply

R84877P May. 4 at 7:08 PM

$PRAX Would love to close over $340

0 · Reply

CharlieeMungerTWITS May. 4 at 2:14 PM

$PRAX I see you two $UNCY !!!!

0 · Reply

Trainguy1 May. 2 at 12:47 PM

$PRAX I’ve seen estimates ranging from May 1 through May 15 for when PRAX will hold their Q1 2026 earnings call. It didn’t happen yesterday. I will check PRAX’s website daily for the date.

0 · Reply

3_19 May. 1 at 5:28 PM

$PRAX why all of the 40 share bids ? Anyone ?

1 · Reply

Biotechster Apr. 30 at 4:34 PM

$PRAX Today is Rank Day cutoff. We graduate to Midcap Russell 1000 in June! We are cap until June 26th then run up to PUDFA date in September! Should see more fireworks by then!

2 · Reply

3_19 Apr. 30 at 4:12 PM

$PRAX what‘s that I smell ? Shorts burning !

0 · Reply

Market Cap	9.25B
Revenue (ttm)	0.00
Net Income (ttm)	-303.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	426,100
Avg Vol	416,456
Day's Range	N/A - N/A
Shares Out	27.88M
Stochastic %K	77%
Beta	2.76
Analysts	Strong Sell
Price Target	$648.65